| Combination of | |
|---|---|
| Bupropion | Norepinephrine/dopamine reuptake inhibitor |
| Zonisamide | Sulfonamide anticonvulsant |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| ATC code | ? |
| (what is this?) (verify) |
|
Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.[1] It is being developed by Orexigen Therapeutics. It has undergone phase 2 tests and is currently waiting for phase 3 testing to commence. The combination consists of two already US FDA approved prescription medications for other ailments.[2] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.
Empatic originally had the name Excalia but had its name changed.[3]